Sanofi touts Acomplia for diabetes

Sanofi-Aventis has told a gathering of the American Diabetes Association that its blockbuster weight drug Acomplia helped overweight diabetics control blood sugar levels and lose weight. Twice as many patients taking Acomplia were able to manage levels of HbA1c compared to patients on a placebo. That's good news for Sanofi, which is touting Acomplia -- rimonabant -- as a drug that can treat a cluster of ailments. Analysts peg potential Acomplia sales at $1 billion per year. The study included people with type 2 diabetes.

- read this story from the International Herald Tribune for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.